

Freedom of Information request 99-22

Request

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following two questions.

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent
- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
- Atezolizumab + Nab-paclitaxel/Paclitaxel
- Capecitabine as a single agent
- Carboplatin or Cisplatin as a single agent
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Lapatinib
- Neratinib
- Parp Inhibitors (Olaparib/Talazoparib)
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Pembrolizumab
- Pertuzumab + Trastuzumab + Docetaxel
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Trastuzumab as a single agent or in combination
- Trastuzumab emtansine
- Transtuzumab deruxtecan
- Vinorelbine as a single agent
- Any other active systemic anti-cancer therapy

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, letrozole) as a single agent?

Response

At present, due to a reporting issue, this information is not held as defined in Section 17, Freedom of Information (Scotland) Act 2002.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **99-22** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.